cagrilintide semaglutide cagrisema phase 3 results 2024 2025 Novo Nosedives on Underwhelming III Weight-Loss Data cagrisema cagrilintide semaglutide phase 3

Clinical trials of FDA-approved semaglutide and tirzepatide show the difference clearly: Semaglutide patients lose about 15% of total body weight Tirzepatide patients lose approximately 21% Both medications can cause mild gastrointestinal side effects, but tirzepatide is often better tolerated, with many patients reporting fewer symptoms

The landmark SUSTAIN clinical trial series evaluated semaglutide in thousands of patients with type 2 diabetes, providing data on various metabolic parameters including lipid profiles

Data from the STEP trials demonstrate that weight loss often increases as the dose increases, with significant reductions typically occurring between months 2 and 6 of treatment

Be kind to yourself throughout the process

We can repeat this medical success story for semaglutide. The researchers warned that cheaper treatments would not address the structural drivers of obesity, including food insecurity, poverty, urbanisation and commercial food environments, and said that coordinated policies and procurement planning would be needed to realise the benefits